PROTALIX BIOTHERAP is trading at 449.40 as of the 21st of September 2021, a -4.38 percent decrease since the beginning of the trading day. The stock's open price was 470.0. Equity ratings for PROTALIX BIOTHERAP are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of August 2021 and ending today, the 21st of September 2021. Click here to learn more.
Check how we calculate scores


Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company was founded in 1993 and is headquartered in Karmiel, Israel. PROTALIX BIOTHERAP operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 207 people. more on PROTALIX BIOTHERAP
PROTALIX BIOTHERAP is not yet fully synchronised with the market data
PROTALIX BIOTHERAP is way too risky over 90 days horizon
PROTALIX BIOTHERAP appears to be risky and price may revert if volatility continues
The company reported the revenue of 52.57 M. Net Loss for the year was (13.66 M) with profit before overhead, payroll, taxes, and interest of 52.02 M.
PROTALIX BIOTHERAP has accumulated about 70.43 M in cash with (28.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.55.
Roughly 22.0% of the company outstanding shares are owned by corporate insiders
CEODror Bashan  (View All)
Thematic Classifications
Active investing themes PROTALIX currently participates. (view all). An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of PROTALIX BIOTHERAP's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedOvervalued
PROTALIX BIOTHERAP (PLX) is traded on Tel Aviv Stock Exchange in Israel and employs 207 people. The company currently falls under 'Large-Cap' category with current market capitalization of 23.05 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PROTALIX BIOTHERAP's market, we take the total number of its shares issued and multiply it by PROTALIX BIOTHERAP's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. PROTALIX BIOTHERAP operates under Healthcare sector and is part of Biotechnology industry. The entity has 45.38 M outstanding shares. PROTALIX BIOTHERAP has accumulated about 70.43 M in cash with (28.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.55.
Check PROTALIX BIOTHERAP Probability Of Bankruptcy

PROTALIX Stock Price Odds Analysis

What are PROTALIX BIOTHERAP's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of PROTALIX BIOTHERAP jumping above the current price in 90 days from now is about 79.21%. The PROTALIX BIOTHERAP probability density function shows the probability of PROTALIX BIOTHERAP stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon PROTALIX BIOTHERAP has a beta of -719.301 indicating as returns on its benchmark rise, returns on holding PROTALIX BIOTHERAP are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, PROTALIX BIOTHERAP is expected to outperform its benchmark. In addition to that, the company has an alpha of 305.7035, implying that it can generate a 305.7 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 449.4HorizonTargetOdds Up 449.4 
20.74%90 days
Based on a normal probability distribution, the odds of PROTALIX BIOTHERAP to move above the current price in 90 days from now is about 79.21 (This PROTALIX BIOTHERAP probability density function shows the probability of PROTALIX Stock to fall within a particular range of prices over 90 days) .


Investors will always prefer to have the highest possible return on investment while minimizing volatility. PROTALIX BIOTHERAP market risk premium is the additional return an investor will receive from holding PROTALIX BIOTHERAP long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in PROTALIX BIOTHERAP. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although PROTALIX BIOTHERAP's alpha and beta are two of the key measurements used to evaluate PROTALIX BIOTHERAP's performance over the market, the standard measures of volatility play an important role as well.

PROTALIX Stock Against Markets

Picking the right benchmark for PROTALIX BIOTHERAP stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in PROTALIX BIOTHERAP stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for PROTALIX BIOTHERAP is critical whether you are bullish or bearish towards PROTALIX BIOTHERAP at a given time.

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with PROTALIX BIOTHERAP stock to make a market-neutral strategy. Peer analysis of PROTALIX BIOTHERAP could also be used in its relative valuation, which is a method of valuing PROTALIX BIOTHERAP by comparing valuation metrics with similar companies.

PROTALIX BIOTHERAP Corporate Directors

PROTALIX BIOTHERAP corporate directors refer to members of a PROTALIX BIOTHERAP board of directors. The board of directors generally takes responsibility for the PROTALIX BIOTHERAP's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of PROTALIX BIOTHERAP's board members must vote for the resolution. The PROTALIX BIOTHERAP board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Roger Kornberg - Independent DirectorProfile
Amos BarShalev - Independent DirectorProfile
Aharon Schwartz - Independent DirectorProfile
David Granot - Independent DirectorProfile
Please check Your Equity Center. Note that the PROTALIX BIOTHERAP information on this page should be used as a complementary analysis to other PROTALIX BIOTHERAP's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Tools for PROTALIX Stock

When running PROTALIX BIOTHERAP price analysis, check to measure PROTALIX BIOTHERAP's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PROTALIX BIOTHERAP is operating at the current time. Most of PROTALIX BIOTHERAP's value examination focuses on studying past and present price action to predict the probability of PROTALIX BIOTHERAP's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move PROTALIX BIOTHERAP's price. Additionally, you may evaluate how the addition of PROTALIX BIOTHERAP to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk